Target intelligence / Profile preview

Ubiquitin-related modifier 1 (URM1)

Target
URM1
Molecular classification
Ubiquitin-like protein, Sulfur carrier protein, Protein modifier (post-translational modification effector), Other
01

Overview

Ubiquitin-related modifier 1 (URM1) is a highly conserved ubiquitin-like protein present from yeast to humans, characterized structurally by a β-grasp fold[1][8]. Functionally, URM1 has a dual role: (1) as a protein modifier, it forms covalent conjugates with other proteins in a process termed urmylation—an atypical post-translational modification that is often triggered by oxidative stress and facilitated by its activating enzyme, Uba4 (or MOCS3 in humans)[1][2][4][5][7]. Unlike traditional ubiquitin or other ubiquitin-like pathways, URM1 conjugation is independent of E2/E3 enzymes and is linked to direct redox regulation and cysteine persulfidation[4][5]. (2) As a sulfur carrier protein for tRNA thiolation, URM1 delivers sulfur to specific tRNAs, which is essential for modifying the wobble uridine of tRNA anticodons via the Ncs2-Ncs6 sulfur–transferase complex, optimizing translational efficiency and cellular stress responses[5][6][7]. Loss of URM1-dependent tRNA modifications is associated with broad cellular dysfunction, with links to cancer and neurodegenerative diseases through defective protein translation and stress adaptation[5]. No direct small molecule drugs, clinical biomarkers, or safety concerns are currently identified for URM1, and it is not considered a classical therapeutic target such as an enzyme, receptor, or transporter[1][5][6][7]. URM1 is mainly of interest in fundamental cell biology and evolutionary studies of ubiquitin-like protein modification systems. Key facts: - URM1 is both a post-translational modifier (urmylation substrate conjugator) and a sulfur transfer protein for tRNA modification[1][2][3][5][6][7]. - URM1-mediated sulfur transfer and urmylation are integral to translation and oxidative stress adaptation, but not directly targeted by drugs or established as direct therapeutic targets at present[1][5][6][7]. - Disease links arise from loss of its tRNA modification function—not from targeting the protein directly.

Other names
Ubiquitin-related modifier 1 homologC9orf74MGC2668URM1
02

Biological functions

Protein urmylation (protein modification via covalent conjugation)tRNA thiolation (transfer of sulfur to tRNA)Oxidative stress responseNutrient sensingCellular stress responseProtein phase separation/condensate formation
03

Disease associations

Cancer (disturbance in tRNA modification linked to cancer[5])Neurodegenerative disease (disturbance in tRNA modification linked to neurodegenerative disease[5])Other

Beyond the preview

Go deeper on Ubiquitin-related modifier 1 (URM1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ubiquitin-related modifier 1 (URM1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call